drugset
drugset / Trial / NCT02123927

Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

NCT02123927 ↗

Phase 1 Completed 108 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study was to evaluate the single dose safety and pharmacokinetics of TAK-438 in healthy Japanese men.

Timeline

Start
2007-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 1 mg Oral
Subject Vonoprazan Other / unclassified 5 mg Oral
Subject Vonoprazan Other / unclassified 10 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral
Subject Vonoprazan Other / unclassified 40 mg Oral
Subject Vonoprazan Other / unclassified 80 mg Oral
Subject Vonoprazan Other / unclassified 120 mg Oral

Indications

No indication recorded.